Search clinical trials for: intrahepatic Cholangiocarcinoma

Total 1219 results

Mayo Clinic

Not yet recruiting

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Zhiyong Huang

Not yet recruiting

Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Yongyi Zeng

Not yet recruiting

Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

Intrahepatic Cholangiocarcinoma
City of Hope Medical Center

Recruiting

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC) (LyMIC)

Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic | Cholangiocarcinoma Resectable | Cholangiocarcinoma; Liver

United States, Japan
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Intrahepatic Cholangiocarcinoma

China
Francesco De Cobelli
A.O. Ospedale Papa Giovanni XXIII; Cardarelli Hospital; AOU Pisana, Pisa, Italy

Recruiting

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (PM-CARE)

Intrahepatic Cholangiocarcinoma

Italy
Shandong Cancer Hospital and Institute

Recruiting

First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC

Intrahepatic Cholangiocarcinoma

China
City of Hope Medical Center

Recruiting

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer (ELUCIDATE)

Hepatocellular Carcinoma | Primary Liver Cancer | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Hepatic Cancer | Hepatic Carcinoma | Primary Liver Carcinoma

United States, Japan
Fudan University

Recruiting

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Intrahepatic Cholangiocarcinoma

China
Fudan University

Not yet recruiting

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
Oslo University Hospital

Recruiting

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) (TOMCAT)

Intrahepatic Cholangiocarcinoma | Chemotherapy Effect

Norway
Nanfang Hospital, Southern Medical University

Recruiting

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Lei ZHAO

Recruiting

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Intrahepatic Cholangiocarcinoma

China
West China Hospital

Recruiting

A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Machine Learning

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

China
Jazz Pharmaceuticals

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer | HER2 Gene Mutation

United States, Puerto Rico
Qilu Hospital of Shandong University
BeiGene

Recruiting

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Cholangiocarcinoma

United States
Tyra Biosciences, Inc

Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)

Solid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma

United States
Rutgers, The State University of New Jersey

Recruiting

Liver Transplantation in Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic

United States
Wuhan Union Hospital, China

Not yet recruiting

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Cancer | Immunotherapy | Tislelizumab | Surufatinib | Angiogenesis Inhibitors | Antineoplastic Agents, Immunological
AstraZeneca

Recruiting

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (ARTEMIDE-Bil01)

Biliary Tract Cancer

France, Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Canada, Germany, Brazil, China, India, Japan, Taiwan, Australia, Thailand, Hong Kong, Denmark, Turkey, Poland, Norway
University of California, Davis
National Cancer Institute (NCI)

Recruiting

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) (LIVELONG)

Oligoprogressive | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Small Bowel Cancer | Intrahepatic Cholangiocarcinoma | Gall Bladder Cancer | Extrahepatic Cholangiocarcinoma | Appendiceal Cancer | Biliary Cancer | Gastroesophageal-junction Cancer

United States
Azienda Sanitaria Ospedaliera
Istituto Oncologico Veneto IRCCS

Recruiting

LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA) (LIRICA)

Intrahepatic Cholangiocarcinoma

Italy
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Intrahepatic Cholangiocarcinoma

United States
Georgetown University
AstraZeneca

Recruiting

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719)

Biliary Tract Cancer | Borderline Resectable Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital of Jinan University; Shenzhen University General...

Recruiting

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma | Digestive System Neoplasms | Intrahepatic Cholangiocarcinoma | First-line Treatment | PD-1 Inhibitor

China
RenJi Hospital

Not yet recruiting

The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases

Biliary Tract Diseases | Intrahepatic Cholangiocarcinoma | Biliary Tract Neoplasms | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Gall Stone
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String (CHORDA-II-p)

Perihilar Cholangiocarcinoma

Netherlands
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Advanced Intrahepatic Cholangiocarcinoma

China
Hua Li

Recruiting

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

China
Lisata Therapeutics, Inc.

Recruiting

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER)

Cholangiocarcinoma | Bile Duct Cancer | Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Gallbladder Cancer | Gall Bladder Cancer | Extrahepatic Cholangiocarcinoma | Gall Bladder Carcinoma

United States, Spain
Charite University, Berlin, Germany
German Research Center for Artificial Intelligence

Not yet recruiting

Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards (ADBoard)

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Cholangiocarcinoma, Perihilar | Fibrolamellar Hepatocellular Carcinoma | Metastasis to Liver

Germany
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Erasmus Medical Center

Recruiting

Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-II)

Adenocarcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Hilar Cholangiocarcinoma | Common Bile Duct Neoplasms

Netherlands, Belgium
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Intrahepatic Cholangiocarcinoma | Durvalumab | Gemcis

China
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; AstraZeneca; Sirtex Medical

Recruiting

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Cholangiocarcinoma | Bile Duct Cancer | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma Metastatic | Metastatic Intrahepatic Cholangiocarcinoma

United States
Chengjun Sui,MD

Not yet recruiting

Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Organoids
Tianjin Medical University Cancer Institute and...

Recruiting

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

China
Institut für Klinische Krebsforschung IKF GmbH...
Incyte Biosciences International Sàrl

Recruiting

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Gene Translocation | FGFR2 Gene Rearrangement

Germany
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Inova Health Care Services

Not yet recruiting

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Intrahepatic Cholangiocarcinoma

United States

Search clinical trials for: intrahepatic Cholangiocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations